Abstract
Certain strains of Escherichia coli producing verotoxin have been isolated in the stools of patients with the haemolytic uraemic syndrome. A platelet aggregating activity has been found in normal plasma after incubation with verotoxin at 37 degrees C for 24 h. This activity, unlike neuraminidase, has an effect that is independent of changing factor VIII related antigen, but requires the IIA and IIIB platelet surface glycoprotein (deficient in thrombasthenia) to mediate its effect. Prostacyclin totally inhibited this effect, but other antiplatelet drugs and heparin were without inhibitory effects.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alon U., Adler S. P., Chan J. C. Hemolytic-uremic syndrome associated with Streptococcus pneumoniae. Report of a case and review of the literature. Am J Dis Child. 1984 May;138(5):496–499. doi: 10.1001/archpedi.1984.02140430072019. [DOI] [PubMed] [Google Scholar]
- De Marco L., Shapiro S. S. Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent. J Clin Invest. 1981 Aug;68(2):321–328. doi: 10.1172/JCI110259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ehrman M. L., Jaffe E. A. Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity. Prostaglandins. 1980 Dec;20(6):1103–1116. doi: 10.1016/0090-6980(80)90063-5. [DOI] [PubMed] [Google Scholar]
- Fong J. S., de Chadarevian J. P., Kaplan B. S. Hemolytic-uremic syndrome. Current concepts and management. Pediatr Clin North Am. 1982 Aug;29(4):835–856. doi: 10.1016/s0031-3955(16)34216-x. [DOI] [PubMed] [Google Scholar]
- Hawiger J., Parkinson S., Timmons S. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets. Nature. 1980 Jan 10;283(5743):195–197. doi: 10.1038/283195a0. [DOI] [PubMed] [Google Scholar]
- Karmali M. A., Steele B. T., Petric M., Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983 Mar 19;1(8325):619–620. doi: 10.1016/s0140-6736(83)91795-6. [DOI] [PubMed] [Google Scholar]
- Keusch G. T., Jacewicz M. Pathogenesis of Shigella diarrhea. VII. Evidence for a cell membrane toxin receptor involving beta1 leads to 4-linked N-acetyl-D-glucosamine oligomers. J Exp Med. 1977 Aug 1;146(2):535–546. doi: 10.1084/jem.146.2.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Levin M., Barratt J. M. Haemolytic uraemic syndrome. Arch Dis Child. 1984 May;59(5):397–400. doi: 10.1136/adc.59.5.397. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lian E. C. The role of increased platelet aggregation in TTP. Semin Thromb Hemost. 1980;6(4):401–415. doi: 10.1055/s-2007-1005112. [DOI] [PubMed] [Google Scholar]
- O'Brien A. D., LaVeck G. D., Thompson M. R., Formal S. B. Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis. 1982 Dec;146(6):763–769. doi: 10.1093/infdis/146.6.763. [DOI] [PubMed] [Google Scholar]
- Olsnes S., Reisbig R., Eiklid K. Subunit structure of Shigella cytotoxin. J Biol Chem. 1981 Aug 25;256(16):8732–8738. [PubMed] [Google Scholar]
- Remuzzi G., Misiani R., Marchesi D., Livio M., Mecca G., de Gaetano G., Donati M. B. Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet. 1978 Oct 21;2(8095):871–872. doi: 10.1016/s0140-6736(78)91573-8. [DOI] [PubMed] [Google Scholar]
- Walsh P. N. Albumin density gradient separation and washing of platelets and the study of platelet coagulant activities. Br J Haematol. 1972 Feb;22(2):205–217. doi: 10.1111/j.1365-2141.1972.tb08801.x. [DOI] [PubMed] [Google Scholar]